IT

Iterum Therapeutics PLCNASDAQ ITRM Stock Report

Last reporting period 30 Sep, 2023

Updated 25 Nov, 2024

Last price

Market cap $B

0.025

Micro

Exchange

XNAS - Nasdaq

ITRM Stock Analysis

IT

Uncovered

Iterum Therapeutics PLC is uncovered by Eyestock quantitative analysis.

Market cap $B

0.025

Dividend yield

Shares outstanding

12.706 B

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous branded penem available. The company is headquartered in Dublin, Dublin. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens to improve the lives of people affected by serious and life-threatening diseases around the world. The firm is focused on developing and commercializing sulopenem, which is an oral and intravenous penem. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The company is also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes, such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms, including methicillin-susceptible staphylococci, and others.

View Section: Eyestock Rating